QT VASCULAR LTD.

(Company Registration No.: 201305911K) (Incorporated in Republic of Singapore)

ISSUE AND ALLOTMENT OF SHARES PURCHASED PURSUANT TO THE EXERCISE OF OPTIONS UNDER THE OPTION SCHEMES ASSUMED/ADOPTED BY QT VASCULAR LTD.

The Board of Directors of QT Vascular Ltd. (the "Company" and together with its subsidiaries, the "Group") is pleased to announce that on 19 December 2014, the Company issued and allotted 1,934,684 ordinary shares in the capital of the Company (the "New Shares") pursuant to the exercise of options granted under the option schemes assumed/adopted by the Company, details of which are as follows:

Options Granted under	Options Exercised	Exercise Price S\$
2005 Stock Plan	1,579,392	0.046125
2010 Equity Incentive Plan	240,000	0.0084375
2013 Stock Plan	115,292	0.068125

The New Shares will rank pari passu in all respects with the existing shares of the Company.

Following the issue and allotment of the New Shares, the number of issued and paid-up shares in the capital of the Company has increased from 758,193,576 to 760,128,260 ordinary shares.

BY ORDER OF THE BOARD

Eitan Konstantino Chief Executive Officer 19 December 2014

The Company was listed on Catalist of the Singapore Exchange Securities Trading Limited (the "SGX-ST") on 29 April 2014. The initial public offering of the Company was sponsored by PrimePartners Corporate Finance Pte. Ltd. (the "Sponsor").

This announcement has been prepared by the Company and its contents have been reviewed by the Sponsor for compliance with the relevant rules of the SGX-ST. The Sponsor has not independently verified the contents of this announcement.

This announcement has not been examined or approved by the SGX-ST and the SGX-ST assumes no responsibility for the contents of this announcement including the correctness of any of the statements or opinions made or reports contained in this announcement.

The contact person for the Sponsor is Mr Mark Liew, Managing Director, Corporate Finance, at 20 Cecil Street, #21-02 Equity Plaza, Singapore 049705, telephone +65 6229 8088.